Barrier Therapeutics, Inc. Receives FDA Approval for Solagé(R) Topical Solution Labeling Expansion

PRINCETON, NJ -- (MARKET WIRE) -- May 03, 2007 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company that develops and markets dermatology products, today announced that the U.S. Food and Drug Administration (FDA) approved the company’s application to add clinical data to the prescribing information for Solagé® (mequinol 2%, tretinoin 0.01%) Topical Solution. The newly added information shows that Solagé treatment for solar lentigines (age spots) is safe and effective in patients with darker skin types.